Cargando…
The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?
The objective of this study is to determine the progress and trends in the treatment and survival of women with early-stage (I–II) epithelial ovarian cancer. Data were obtained from the SEER database between 1988 and 2001. Kaplan–Meier and Cox regressions methods were employed for statistical analys...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359639/ https://www.ncbi.nlm.nih.gov/pubmed/18349835 http://dx.doi.org/10.1038/sj.bjc.6604299 |
_version_ | 1782152882317950976 |
---|---|
author | Chan, J K Fuh, K Shin, J Y Cheung, M K Powell, C B Chen, L-m Kapp, D S Osann, K |
author_facet | Chan, J K Fuh, K Shin, J Y Cheung, M K Powell, C B Chen, L-m Kapp, D S Osann, K |
author_sort | Chan, J K |
collection | PubMed |
description | The objective of this study is to determine the progress and trends in the treatment and survival of women with early-stage (I–II) epithelial ovarian cancer. Data were obtained from the SEER database between 1988 and 2001. Kaplan–Meier and Cox regressions methods were employed for statistical analyses. Of the 8372 patients, the median age was 57 years (range: 12–99 years). A total of 6152 patients (73.4%) presented with stage I and 2220 (26.5%) with stage II disease. Over the periods 1988–1992, 1993–1997, and 1998–2001, 3-year disease-specific survivals increased from 86.1 to 87.2 to 88.8% (P=0.076). The number of patients that underwent lymphadenectomy has increased significantly from 26.2 to 38.7 to 54.2% over the study period (P<0.001). Of those patients who underwent staging procedures with lymphadenectomy, there was no improvement in survival over the three study periods (from 93.2 to 93.5 to 93.1%; P=0.978). On multivariate analysis, younger age, nonclear cell histology, earlier stage, lower grade, surgery, and lymphadenectomy were significant independent prognostic factors for improved survival. After adjusting for surgical staging with lymphadenectomy, the year of diagnosis was no longer an important prognostic factor. In conclusion, the use of lymphadenectomy during surgery for early-stage ovarian cancer has doubled over the last 14 years. The marginal improvement in survival demonstrated over time is potentially attributed to the increased use of staging procedures with lymphadenectomy. |
format | Text |
id | pubmed-2359639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23596392009-09-10 The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? Chan, J K Fuh, K Shin, J Y Cheung, M K Powell, C B Chen, L-m Kapp, D S Osann, K Br J Cancer Clinical Study The objective of this study is to determine the progress and trends in the treatment and survival of women with early-stage (I–II) epithelial ovarian cancer. Data were obtained from the SEER database between 1988 and 2001. Kaplan–Meier and Cox regressions methods were employed for statistical analyses. Of the 8372 patients, the median age was 57 years (range: 12–99 years). A total of 6152 patients (73.4%) presented with stage I and 2220 (26.5%) with stage II disease. Over the periods 1988–1992, 1993–1997, and 1998–2001, 3-year disease-specific survivals increased from 86.1 to 87.2 to 88.8% (P=0.076). The number of patients that underwent lymphadenectomy has increased significantly from 26.2 to 38.7 to 54.2% over the study period (P<0.001). Of those patients who underwent staging procedures with lymphadenectomy, there was no improvement in survival over the three study periods (from 93.2 to 93.5 to 93.1%; P=0.978). On multivariate analysis, younger age, nonclear cell histology, earlier stage, lower grade, surgery, and lymphadenectomy were significant independent prognostic factors for improved survival. After adjusting for surgical staging with lymphadenectomy, the year of diagnosis was no longer an important prognostic factor. In conclusion, the use of lymphadenectomy during surgery for early-stage ovarian cancer has doubled over the last 14 years. The marginal improvement in survival demonstrated over time is potentially attributed to the increased use of staging procedures with lymphadenectomy. Nature Publishing Group 2008-04-08 2008-03-18 /pmc/articles/PMC2359639/ /pubmed/18349835 http://dx.doi.org/10.1038/sj.bjc.6604299 Text en Copyright © 2008 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Chan, J K Fuh, K Shin, J Y Cheung, M K Powell, C B Chen, L-m Kapp, D S Osann, K The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
title | The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
title_full | The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
title_fullStr | The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
title_full_unstemmed | The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
title_short | The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
title_sort | treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress? |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359639/ https://www.ncbi.nlm.nih.gov/pubmed/18349835 http://dx.doi.org/10.1038/sj.bjc.6604299 |
work_keys_str_mv | AT chanjk thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT fuhk thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT shinjy thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT cheungmk thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT powellcb thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT chenlm thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT kappds thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT osannk thetreatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT chanjk treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT fuhk treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT shinjy treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT cheungmk treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT powellcb treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT chenlm treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT kappds treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress AT osannk treatmentandoutcomesofearlystageepithelialovariancancerhavewemadeanyprogress |